Table 1 Summary of the Food and Drug Administration-approved CAR-T cell products.
From: Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Product name | Commercial name | Chimeric antigen receptor structure | Cell resource | Transfection method | Approved indications (date) |
|---|---|---|---|---|---|
Kymriah | Anti CD19-CD8α (hinge+tm)-41BB-CD3ζ | Enriched T cells | Lentivirus | -R/R B-ALL after ≥ 2 lines therapy with aged ≤ 25 years (Aug 2017) -R/R LBCL after ≥ 2 lines therapy (May 2018) -R/R FL after ≥ 2 lines therapy (May 2022) | |
Yescarta | Anti CD19-CD28 (hinge+tm)-CD28-CD3ζ | PBMCs | Retrovirus | -R/R LBCL after≥2 lines of therapy (Oct 2017) -R/R FL after ≥2 lines of therapy (Apr 2021) -LBCL refractory to first-line therapy or relapsing within 12 months of first-line therapy (Apr 2022) | |
Tecartus | Anti CD19-CD28 (hinge+tm)-CD28-CD3ζ | CD19+depleted and CD4+/CD8+ enriched T cells | Retrovirus | -R/R MCL (Jul 2020) -R/R adult B-ALL (Oct 2021) | |
Breyanzi | Anti CD19-IgG4 (hinge)-CD28 (tm)-41BB-CD3ζ | CD4+ and CD8+ T cells separately | Lentivirus | -R/R LBCL after ≥2 lines of therapy (Feb 2021) -LBCL refractory to first-line therapy or relapsing within 12 months of first-line therapy and are not eligible for HSCT (Jun 2022) -R/R CLL/SLL after ≥2 lines of therapy (Mar 2024) -R/R FL after ≥2 lines of therapy (May 2024) | |
Abecma | Anti BCMA-CD8α (hinge+tm)-41BB-CD3ζ | PBMCs | Lentivirus | -R/R MM after ≥4 lines of therapy (Mar 2021) -R/R MM after ≥2 lines of therapy (Apr 2024) | |
Ciltacabtagene autoleucel (cilta-cel) [13] | Carvykti | Dual anti BCMA-CD8α (hinge+tm)-41BB-CD3ζ | Enriched T cells | Lentivirus | -R/R MM after ≥4 lines of therapy (Feb 2022) -R/R MM after ≥1 lines of therapy (Apr 2024) |
